Cardiovascular comorbidities in psoriasis and psoriatic arthritis: Pathogenesis, consequences for patient management, and future research agenda: A report from the GRAPPA 2009 annual meeting

Journal of Rheumatology

Volumn 38, Issue 3, 2011, Pages 567-571

  Boehncke, Wolf Henning ^a   Gladman, Dafna D ^b   Chandran, Vinod ^b  

^a GOETHE UNIVERSITY   (Germany)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Anti tumor necrosis factor agents; Atherosclerosis; Insulin resistance; Myocardial infarction; Psoriasis; Psoriatic arthritis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL PRODUCT; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EFALIZUMAB; ETRETIN; FUMARIC ACID DERIVATIVE; HYDROXYCHLOROQUINE; INTERFERON; LEFLUNOMIDE; LITHIUM SALT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; ONERCEPT; PLACEBO; RETINOID; TERBINAFINE; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; COMORBIDITY; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; OBESITY; PATHOGENESIS; PATIENT MONITORING; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RISK FACTOR;

ARTHRITIS, PSORIATIC; CARDIOVASCULAR DISEASES; COMORBIDITY; CONGRESSES AS TOPIC; FEMALE; HUMANS; MALE; PSORIASIS; SWEDEN;

EID: 79952428975     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.101124     Document Type: Conference Paper

References (39)

1. Schön MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352:1899-912.
2. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496-509.
3. Fitzgerald O, Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther 2009;11:214.
4. McGonagle D, Benjamin M, Tan AL. The pathogenesis of psoriatic arthritis and associated nail disease: not autoimmune after all? Curr Opin Rheumatol 2009;21:340-7.
5. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med 2006;3:e297.
6. Boehncke WH. Immunomodulatory drugs for psoriasis. BMJ 2003;327:634-5.
7. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007;370:272-84. (Pubitemid 47071926)
8. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722-32. (Pubitemid 40365093)
9. Popa C, Netea MG, Radstake T, van der Meer JW, Stalenhoef AF, van Riel PL, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005;64:303-5. (Pubitemid 40193632)
10. Mattey DL, Glossop JR, Nixon NB, Dawes PT. Circulating levels of tumor necrosis factor receptors are highly predictive of mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:3940-8. (Pubitemid 350262319)
11. Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905-12. (Pubitemid 47502736)
12. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982-6.
13. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007;143:1493-9. (Pubitemid 350277763)
14. Mallbris L, Akre O, Granath F, Yin L, Lindelof B, Ekbom A, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19:225-30. (Pubitemid 38461682)
15. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41. (Pubitemid 44547793)
16. Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007;156:271-6. (Pubitemid 46095954)
17. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997;40:1868-72.
18. Ali Y, Tom BD, Schentag CT, Farewell VT, Gladman DD. Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum 2007;56:2708-14. (Pubitemid 47237289)
19. Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009;68:1131-5.
20. Bruce IN, Schentag CT, Gladman DD. Hyperuricemia in psoriatic arthritis: prevalence and associated features. J Clin Rheumatol 2000;6:6-9. (Pubitemid 30127489)
21. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Gomez-Acebo I, Miranda-Filloy JA, Paz-Carreira J, et al. Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum 2009;39:157-62.
22. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med 2005;118:816-26.
23. Tam LS, Shang Q, Li EK, Tomlinson B, Chu TT, Li M, et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 2008;59:1322-31.
24. Eder L, Zisman D, Barzilai M, Laor A, Rahat M, Rozenbaum M, et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol 2008;35:877-82. (Pubitemid 351747131)
25. Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007;57:1074-80. (Pubitemid 47237336)
26. Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 2007;370:2138-51.
27. Sattar N, Crompton P, Cherry L, Kane D, Lowe G, McInnes IB. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2007;56:831-9. (Pubitemid 46399431)
28. Tam L, Li EK, Shang Q, Tomlinson B, Chu TT, Li M, et al. TNF-alpha blockade is associated with reduction of carotid intima-media thickness for patients with active psoriatic arthritis - a pilot study. Ann Rheum Dis 2009;68 Suppl 3:659.
29. Angel K, Provan SA, Gulseth HL, Mowinckel P, Kvien TK, Atar D. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 2009;55:333-8.
30. Boehncke WH, Buerger C, Boehncke S. Co-morbidities in psoriasis vulgaris. Hautarzt 2009;60:116-21.
31. Boehncke S, Thaci D, Beschmann H, Ludwig RJ, Ackermann H, Badenhoop K, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007;157:1249-51. (Pubitemid 350115673)
32. Boehncke WH, Boehncke S, Schon MP. Managing comorbid disease in patients with psoriasis. BMJ 2010;340:b5666.
33. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005;125:61-7. (Pubitemid 40981424)
34. Nast A, Kopp I, Augustin M, Banditt KB, Boehncke WH, Follmann M, et al. German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res 2007;299:111-38. (Pubitemid 46835379)
35. Gerdes S, Zahl VA, Knopf H, Weichenthal M, Mrowietz U. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol 2008;159:1116-23.
36. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
37. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003. (Pubitemid 36712275)
38. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008;58:1031-42.
39. Tamagawa-Mineoka R, Katoh N, Kishimoto S. Platelet activation in patients with psoriasis: increased plasma levels of platelet-derived microparticles and soluble P-selectin. J Am Acad Dermatol 2010;62:621-6.